Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00277316 · ClinicalTrials.gov registry record · Phase 2
Study of XL999 in Patients With Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Symphony Evolution.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00277316 is a Phase 2 study that was terminated before completion, run by Symphony Evolution. The registered enrollment target is 11 participants.
The verdict
NCT00277316, a Phase 2 study, was terminated before completion, sponsored by Symphony Evolution.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic clear cell renal cell carcinoma (RCC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.
Interventions
- DRUG XL999
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00277316
The ClinicalTrials.gov registry entry for NCT00277316 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Symphony Evolution, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XL999 is the first listed.
NCT00277316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00277316 about?
NCT00277316 is a clinical study titled "Study of XL999 in Patients With Metastatic Renal Cell Carcinoma". This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic clear cell renal cell carcinoma (RCC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and ...
What is the current status of trial NCT00277316?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2005-12. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00277316?
The interventions under investigation include: XL999 (DRUG).
Who is sponsoring clinical trial NCT00277316?
This trial is sponsored by Symphony Evolution, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.